Wow - at last the Priority Review announcement is here.
This "represents an important milestone for company" - SI didn't waste too many words.
But, this is darn important!
It bring legitimacy to Mesoblast and kills off all the "if and buts" about the science.
Now it is all there for us to see: a paradigm shift in medical treatment and our company charging towards commercialisation
Bring it on!
GLTASHs
Ann: FDA Accepts BLA for RYONCIL and Agrees to Priority Review, page-11
-
- There are more pages in this discussion • 121 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.065(4.69%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $7.016M | 4.856M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10425 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 44243 | 5 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |